High Prevalence Of Tuberculosis In North America Is Propelling The Growth Of The Pyrazinamide Market
In March 2017, Médecins Sans Frontières (MSF), Partners In Health (PIH), and other medical organizations have launched a major clinical trial that seeks to revolutionize treatment for the toughest strains of tuberculosis (TB), the world’s leading infectious disease killer. The increasing incidence and prevalence of tuberculosis (TB) disease is playing a significant role in the overall development of the Pyrazinamide market . According to the World Health Organization, worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS).In 2019, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.2 million women, and 1.2 million children. TB is present in all countries and age groups. Pyrazinamide is a drug widely used to treat tuberculosis. Furthermore, increasing spending on pharmaceutical industry by key manufacturers are further anticipated to uplift the growth of the Pyrazinamide ma...